Warning Letter: Germiphene

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.

Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders.